Study of LP-184 in Patients With Advanced Solid Tumors
Advanced Solid Tumor · Metastatic Solid Tumor · GBM · TNBC - Triple-Negative Breast Cancer · NSCLC · Pancreatic Adenocarcinoma · DDR Gene Mutation
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 64 (final count)
- Started
- Jun 9, 2023
- Main results expected
- Jul 28, 2026
- Fully finished
- Jul 28, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0
Measured over: 12 months
To determine the MTD of LP-184 based on all available safety (graded by CTCAE v5.0) and PK data.
Measured over: 12 months
To determine the RP2D of LP-184 based on all available safety (graded by CTCAE v5.0), PK, PD and efficacy data
Measured over: 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05933265 · record last updated 2026-05-04 · checked 2026-11-09 15:47 UTC